Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980984 | 0.79 | HCAR3 (0.58) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL1283854 | 0.79 | MAPT (0.54) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL11048929 | 0.79 | MAPT (0.65) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL762635 | 0.78 | KAT2B (0.60) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL762553 | 0.78 | SMN1; SMN2 (0.60) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL6024313 | 0.76 | HCAR3 (0.62) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL15239673 | 0.76 | MAPT (0.61) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL17819083 | 0.76 | KAT2B (0.72) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL20529066 | 0.76 | HCAR3 (0.53) | MAPTHCAR3PKMPOLBKAT2B | |
| SCHEMBL27847152 | 0.76 | MAPT (0.58) | MAPTHCAR3PKMPOLBKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138420-B2 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050203158-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1529046-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014905-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203158-A1 | Substituted benzimidazole compounds | ITK, BLK, SBK1 | MAPT 4228/4885HCAR3 1724/4885PKM 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.